Viewing data from:

WIXELA INHUB

ANDA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | A208891 | MYLAN PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ADVAIR DISKUS 100/50(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Wixela Inhub (2023)

Total Spending

$273.0M

Total Claims

957,338

Beneficiaries

320,592

Avg Cost/Unit

$2.87

Spending Trend

$208.0M(2019)→$336.8M(2020)→$366.9M(2021)→$326.8M(2022)→$273.0M(2023)

YoY Change:-4.2%

5yr CAGR:-2.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 21, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 0.1MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▴

POWDER;INHALATION | Approved: Jan 30, 2019

No patent or exclusivity listings for this strength.

#002 — 0.25MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▾

POWDER;INHALATION | Approved: Jan 30, 2019

#003 — 0.5MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▾

POWDER;INHALATION | Approved: Jan 30, 2019